Lotriderm
In brief
- Lotriderm is a prescription-only medicine (POM) in the UK.
- Lotriderm is used for fungal skin infections such as athlete’s foot (tinea pedis), jock itch (tinea cruris) and ringworm (tinea corporis). It combines clotrimazole (an imidazole antifungal that inhibits fungal ergosterol synthesis) with betamethasone dipropionate (a potent topical corticosteroid that reduces inflammation, redness and itching).
- Usual dosage for adults and those 17 years and older: apply a thin film to the affected area twice daily (morning and evening). Treat tinea corporis/cruris for up to 2 weeks and tinea pedis for up to 4 weeks; do not exceed 45 g per week.
- Administered topically as a cream (common formulation: 1% clotrimazole / 0.05% betamethasone dipropionate, typically in 15 g or 30 g tubes).
- Symptomatic relief of inflammation and itching is often noticed within 24–48 hours; antifungal eradication and visible clearance of infection can take several days to weeks depending on severity.
- The local effect after application typically lasts until the next dose (hence twice-daily dosing, roughly 12 hours); the full treatment course is usually up to 2–4 weeks depending on the condition being treated.
- There is no specific interaction with oral alcohol for topical use, but avoid alcohol-containing skin products on the treated area; exercise general caution with alcohol if there is concern about systemic corticosteroid exposure or other health issues.
- The most common side effect is local burning or irritation at the application site.
- Would you like to try Lotriderm without a prescription?
Legal status and availability in the UK
Lotriderm (clotrimazole with betamethasone dipropionate) is a prescription-only medicine (POM) in the UK.
In our online pharmacy, Lotriderm is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.
Basic Lotriderm information
- INN (international nonproprietary name): Clotrimazole and betamethasone dipropionate.
- Brand names available in the United Kingdom: Lotriderm.
- ATC code: D07XC01.
- Forms and dosages: cream 1% clotrimazole / 0.05% betamethasone dipropionate (0.643 mg betamethasone dipropionate per 1 g cream), typically in 15 g and 30 g tubes.
- Manufacturers in the United Kingdom: Organon (Lotriderm).
- Registration status in the United Kingdom: Prescription-only medicine (POM).
- OTC / Rx classification: Prescription-only medicine (POM).
Typical use
Patients commonly want fast itch relief alongside a cure for the fungal rash. Lotriderm pairs an antifungal with a topical steroid to meet that expectation.
Short courses of a combination cream often work well for localised tinea corporis and tinea cruris, and for moderate tinea pedis with inflammation.
Misuse commonly seen includes extended courses beyond the recommended duration, applying under occlusion and use on children where safety is not established.
Typical use is twice‑daily application for up to 2 weeks for body/jock itch and up to 4 weeks for athlete’s foot in adults and those 17 years and older.
The duration should be agreed at the start and the response reviewed at 1–2 weeks, with escalation to a GP or specialist if the presentation is unusual.
What Lotriderm contains and how it works
INN, mechanism and formulation basics
The active ingredients are clotrimazole and betamethasone dipropionate by INN.
The product is a fixed‑dose topical combination pairing an imidazole antifungal with a potent topical corticosteroid.
Clotrimazole is present at 1% and betamethasone dipropionate at 0.05%, equivalent to 0.643 mg betamethasone dipropionate per gram of cream as stated in product data.
Clotrimazole acts by inhibiting ergosterol synthesis in fungal cell membranes, disrupting fungal growth.
Betamethasone dipropionate reduces inflammation and itching by suppressing inflammatory mediators at the application site.
The anti‑inflammatory action improves symptom control quickly and can help adherence to the antifungal regimen.
Combination rationale: symptomatic control speeds functional recovery and patient satisfaction, but the steroid may mask persistent infection if misused.
The cream is the usual dosage form.
Mechanism Summary:
- Antifungal action: clotrimazole inhibits fungal ergosterol synthesis.
- Steroid anti‑inflammatory action: betamethasone dampens local inflammatory response, reducing itch and redness.
Lotriderm is prescription‑only in the UK, and extensive use can increase the risk of systemic steroid exposure.
Indications and practical usage scenarios
Typical clinical and everyday cases
This combination is indicated for superficial fungal infections with significant inflammation, commonly tinea corporis, tinea cruris and tinea pedis.
Standard adult dosing is a thin film applied twice daily to the affected area for up to 2 weeks for corporis/cruris and up to 4 weeks for pedis.
The combination suits acute, well‑localised lesions with clear borders and moderate inflammation without signs of secondary bacterial infection.
Another common case is an adult with long‑standing athlete’s foot who develops inflammatory vesicles and needs both symptom relief and antifungal therapy.
It should not be used for facial or perioral rashes, intertrigo with broken skin, diaper dermatitis or suspected scabies.
Where diagnostic uncertainty exists, a GP or dermatologist should assess the rash, and fungal culture may be considered if lesions recur quickly after stopping treatment.
- Decision point: Localised, inflamed tinea → consider combination cream.
- Decision point: Non‑inflamed, uncomplicated tinea → prefer antifungal monotherapy.
Dosage forms, strengths and brands
Availability and packaging
The usual form is a cream containing 1% clotrimazole and 0.05% betamethasone dipropionate, supplied in 15 g and 30 g tubes. In the UK the brand is Lotriderm (Organon).
ATC classification is D07XC01 (betamethasone and clotrimazole).
| Tube size | Expected coverage |
|---|---|
| 15 g | Small groin lesion for up to 2 weeks |
| 30 g | Moderate area coverage or up to 4 weeks for athlete’s foot |
How to apply: practical technique and dosing
Step‑by‑step application and quantity guidance
Effective and safe use depends on correct application technique and adherence to dose limits.
Clean and dry the affected area before applying the cream.
Apply a thin film twice daily, in the morning and evening, covering the lesion and a small margin of surrounding skin.
A thin film means enough cream to cover the skin without excess or visible residue.
Do not exceed 45 g per week of the cream as stated in product data.
Avoid occlusion unless specifically directed by a prescriber.
Do not apply on or near the eyes, mouth, mucosal or intravaginal areas.
When using on the feet, dry thoroughly between toes to reduce maceration prior to application.
If a dose is missed, apply as soon as remembered but do not double up doses.
Advise patients to stop treatment and consult if there is no improvement within the recommended course or if local adverse effects develop.
Contraindications and cautions
Absolute and relative contraindications
Absolute contraindications include known hypersensitivity to clotrimazole, betamethasone dipropionate or any excipients and use on ocular, oral or intravaginal sites.
Use is not established and is generally avoided in children under 17 years unless specifically prescribed by a clinician.
Relative cautions include extensive application over large areas, use under occlusion, pregnancy and breastfeeding unless deemed essential, and atrophic or damaged skin.
Also exercise caution in patients with recent systemic corticosteroid use or a history of HPA‑axis suppression.
Before use, check age, pregnancy/breastfeeding status, lesion extent, prior topical steroid use and presence of broken skin.
When in doubt about safety or extent of infection, speak to a GP or pharmacist.
Side effects, monitoring and what to advise patients
Common adverse events and red‑flag symptoms
Common local reactions include burning, stinging, irritation, dryness and transient redness at the application site.
Prolonged use may cause skin atrophy, folliculitis, acneiform eruptions, maceration or secondary bacterial infection.
Excessive or long‑term use can increase the risk of systemic corticosteroid effects, including HPA‑axis suppression in vulnerable patients.
Stop treatment and seek medical advice if you develop worsening erythema, spreading rash, blistering or signs of bacterial infection such as increasing pain or purulent discharge.
Report systemic symptoms such as unexplained weight gain, new bruising or Cushingoid features if treatment has been extensive.
See a GP if there is no improvement by the end of the recommended course or if lesions recur promptly after stopping.
When to see a GP:
- Worsening or spreading rash despite treatment.
- Signs of secondary infection or systemic symptoms.
- No improvement after recommended treatment duration.
Interactions, systemic absorption and special populations
Risk stratification for absorption and drug interactions
Topical application normally yields low systemic exposure, but absorption increases with large surface area, prolonged use, damaged skin or occlusion.
Children have a higher surface area to body weight ratio and are at greater risk of systemic corticosteroid effects; safety under 17 is not established.
Concurrent systemic corticosteroids or medicines that may amplify steroid effects should be reviewed with the prescriber.
Elderly patients may be more prone to skin fragility and increased local absorption, so monitor for atrophy and systemic signs.
In pregnancy and breastfeeding, avoid use unless essential.
No routine dose adjustment is required for hepatic or renal impairment, but maintain vigilance for systemic steroid effects when larger areas are treated.
| Population | Relative absorption risk |
|---|---|
| Children <17 years | High — avoid unless prescribed |
| Elderly | Moderate — monitor for atrophy and systemic signs |
| Pregnant/Breastfeeding | Use only if essential |
| Large/damaged skin areas | High — increased systemic absorption risk |
Monitoring tips: limit the treated area and duration, and seek GP evaluation for prolonged use.
Combination versus single-agent treatment
When to choose combination therapy vs monotherapy
Combination antifungal‑steroid creams provide faster symptomatic relief than antifungal monotherapy but carry steroid‑related risks if misused.
Other combinations include Daktacort (miconazole/hydrocortisone), while monotherapy options include Canesten (clotrimazole) and Lamisil (terbinafine).
Choose a combination when inflammation significantly impairs quality of life or prevents adherence to treatment, for short, supervised courses.
Prefer antifungal monotherapy for uncomplicated, non‑inflamed tinea or for longer‑term management to avoid steroid sequelae such as atrophy.
| Feature | Combination cream | Antifungal monotherapy |
|---|---|---|
| Onset of symptom relief | Faster due to steroid | Slower; addresses fungus directly |
| Spectrum | Broad antifungal plus steroid | Depends on agent (clotrimazole vs terbinafine) |
| Steroid potency | Potent topical steroid present | None |
| Suitable indications | Inflamed tinea corporis/cruris, inflammatory pedis | Non‑inflamed tinea, long‑term use |
Follow MHRA and NHS guidance on conservative use of topical corticosteroids and prefer monotherapy where appropriate.
Prescribing and legal status
Lotriderm (clotrimazole with betamethasone dipropionate) is a prescription-only medicine (POM) in the UK. Supply is normally via an NHS or private prescription.
Storage, transport and disposal
Practical handling and safety
Store the cream at 20–25°C and avoid freezing as stated in product information.
Keep tubes tightly closed and out of reach of children.
Avoid prolonged heat exposure during transport, for example leaving a tube in a hot car for hours.
Do not flush or dispose of unused medicines down household drains or bins; follow local NHS or pharmacy returns policy for pharmaceutical waste.
Return partially used tubes to the dispensing pharmacy for safe disposal.
Counselling points
Key counselling points
Before use, confirm age (17+), pregnancy/breastfeeding status, lesion location and size, prior steroid use and current systemic medications.
Apply a thin film twice daily; the maximum is 45 g per week.
Symptom improvement is expected in days, but the complete antifungal course is up to 2–4 weeks depending on the site.
Stop treatment and seek GP review if there is a worsening rash, signs of infection or no improvement after the prescribed course.
Delivery across the United Kingdom
| City | Region | Delivery time |
|---|---|---|
| London | England | 9–21 days |
| Birmingham | England | 9–21 days |
| Manchester | England | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | England | 9–21 days |
| Liverpool | England | 9–21 days |
| Bristol | England | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Sheffield | England | 9–21 days |
| Newcastle Upon Tyne | England | 9–21 days |
| Nottingham | England | 9–21 days |
| Leicester | England | 9–21 days |
| Plymouth | England | 9–21 days |
| Coventry | England | 9–21 days |
FAQs, red flags and referral guidance
Quick answers and when to refer to GP or dermatology
Can children use this product? Safety and efficacy are not established under 17 years and use is not recommended unless prescribed.
How long to see improvement? Symptoms often improve within days, but reassess at the end of the recommended course.
Can I use it on the face? Do not use on facial or perioral areas or mucous membranes.
Red flags requiring GP or dermatology referral include spreading pustules, systemic symptoms, non‑healing after the recommended course, extensive involvement greater than about 10% body surface area, facial or genital mucosal involvement, and suspected scabies.
Stop treatment and refer urgently if there are signs of secondary bacterial infection or systemic steroid effects.
Consider fungal culture or dermatology referral for recurrent or treatment‑resistant tinea or for immunosuppressed patients.
If systemic signs are present: stop treatment and seek urgent GP or A&E advice.
